Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:47:20.493Z.
Calculation as of: 2026-10-06T15:47:20.493Z.
Quote observation: 2026-10-06T15:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 820e6844a86ebcce87b4cbc727545bf8fd5f2e7882f78b89935f6b0fc3bd738c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Larimar Therapeutics, Inc.
Market Cap
$297.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$290.79M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$303.53M
EV/EBITDA Ratio
N/A
TTM Avg
22.81x
3Y Avg
22.81x
5Y Avg
22.81x
Market Cap
$289.25M
EV/EBITDA Ratio
N/A
TTM Avg
18.83x
3Y Avg
18.83x
5Y Avg
18.83x
Market Cap
$285.94M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$309.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.21M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.60M
EV/EBITDA Ratio
N/A
TTM Avg
10.42x
3Y Avg
23.40x
5Y Avg
23.40x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $297.62M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $290.97M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $290.79M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $303.53M | N/A | 22.81x | 22.81x | 22.81x |
| Abeona Therapeutics Inc. (ABEO)vs › | $289.25M | N/A | 18.83x | 18.83x | 18.83x |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.94M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $309.62M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $284.21M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.60M | N/A | 10.42x | 23.40x | 23.40x |
| Fate Therapeutics, Inc. (FATE)vs › | $278.87M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
